UBS AM
YMAB

UBS AM’s Y-mAbs Therapeutics YMAB Stock Holding History

UBS AM’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-52,356
Closed -$410K – 2705
2024
Q4 		$410K Buy
52,356
+7,765
+17% +$94.6K ﹤0.01% 2583
2024
Q3 		$586K Sell
44,591
-13,708
-24% -$174K ﹤0.01% 2606
2024
Q2 		$704K Buy
+58,299
New +$787K ﹤0.01% 2528
2023
Q1 		– Sell
-15,600
Closed -$76.1K – 2726
2022
Q4 		$76.1K Hold
15,600
– – ﹤0.01% 2503
2022
Q3 		$225K Hold
15,600
– – ﹤0.01% 2572
2022
Q2 		$236K Hold
15,600
– – ﹤0.01% 2541
2022
Q1 		$185K Hold
15,600
– – ﹤0.01% 2692
2021
Q4 		$253K Sell
15,600
-7,819
-33% -$167K ﹤0.01% 2716
2021
Q3 		$668K Hold
23,419
– – ﹤0.01% 2361
2021
Q2 		$792K Buy
23,419
+10,519
+82% +$338K ﹤0.01% 2335
2021
Q1 		$390K Sell
12,900
-3,849
-23% -$158K ﹤0.01% 2451
2020
Q4 		$829K Hold
16,749
– – ﹤0.01% 2080
2020
Q3 		$643K Buy
16,749
+1,000
+6% +$39.8K ﹤0.01% 2019
2020
Q2 		$680K Buy
15,749
+7,749
+97% +$293K ﹤0.01% 1977
2020
Q1 		$209K Hold
8,000
– – ﹤0.01% 2261
2019
Q4 		$250K Buy
+8,000
New +$237K ﹤0.01% 2417

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

UBS AM's YMAB Position: Q1 2025 in Review

UBS AM sold out of Y-mAbs Therapeutics (YMAB) in Q1 2025, closing a stake of 52,356 shares — an estimated $410K sold.

UBS AM first reported a position in YMAB in Q4 2019 and held it in 16 quarters. The position peaked at $829K in Q4 2020. 102 funds tracked by Wall St. Rank hold YMAB as of Q1 2025.

  • UBS AM reported no remaining Y-mAbs Therapeutics position as of Q1 2025 after selling out during the quarter.
  • UBS AM sold 52,356 Y-mAbs Therapeutics shares in Q1 2025, an estimated $410K.
  • UBS AM first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 16 quarters.
  • UBS AM's Y-mAbs Therapeutics position peaked at $829K in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2025.

Based on UBS AM's 13F filing for Q1 2025, filed 19 May 2025.